Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enclomiphene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 10/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | EBP | Q15125 | 5/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enclomiphene SCHEMBL8040981 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Zuclomiphene SCHEMBL223472 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL220953 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL20942789 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Clomiphene SCHEMBL27599894 | 1.00 | KDM4E (1.00) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8616232 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8614802 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8614814 | 0.94 | KMT2A (0.89) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8612826 | 0.93 | KMT2A (0.87) | KDM4EKMT2ACYP2D6MEN1LMNA | |
| Citric Acid SCHEMBL8613135 | 0.93 | KMT2A (0.87) | KDM4EKMT2ACYP2D6MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12569624-B2 | Devices, methods and compositions for reproductive organs | FEMASYS INC. (US) | 2026-03-10 | — | — | US | claimed |
| US-12544387-B2 | Methods and compositions for testosterone production | SEPAH SAVIZ CAMERON (US) | 2026-02-10 | — | — | US | claimed |
| US-12533364-B2 | Methods and compositions for testosterone production | Saviz SEPAH (US) | 2026-01-27 | — | — | US | claimed |
| US-12533363-B2 | Methods and compositions for testosterone production | Sepah, Saviz (US) | 2026-01-27 | — | — | US | claimed |
| EP-4680248-A1 | PRODUCTS OF MANUFACTURE AND THERAPEUTIC COMPOSITIONS FOR TREATING, AMELIORATING OR PREVENTING VIRAL INFECTIONS AND METHODS FOR MAKING AND USING THEM | Topelia Aust Limited (ACN 652 771 670) (AU) | 2026-01-21 | — | — | EP | claimed |
| US-20250295670-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SEPAH SAVIZ CAMERON (US) | 2025-09-25 | — | — | US | claimed |
| US-20250288598-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | Maximus Health, Inc. | 2025-09-18 | — | — | US | claimed |
| US-20250281505-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | Maximus Health, Inc. | 2025-09-11 | — | — | US | claimed |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | TOPELIA AUST LIMITED (ACN 652 771 670) (AU) | 2025-08-28 | — | — | US | claimed |
| US-20250268915-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | Maximus Health, Inc. (US) | 2025-08-28 | — | — | US | claimed |
| EP-1216024-A4 | FORMULATION FOR MENOPAUSAL WOMEN | DRUGTECH CORP (US) | 2005-02-02 | — | — | EP | claimed |
| EP-1471917-A1 | USE OF PDE5 INHIBITORS SUCH AS SILDENAFIL IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME | Pfizer Limited (GB) | 2004-11-03 | — | — | EP | claimed |
| US-20040029891-A1 | Use of PDE5 inhibitors in the treatment of polycystic ovary syndrome | PFIZER INC. | 2004-02-12 | — | — | US | claimed |
| WO-2003066061-A1 | USE OF PDE5 INHIBITORS SUCH AS SILDENAFIL IN THE TREATMENT OF POLYCYSTIC OVARY SYNDROME | PFIZER LIMITED (GB) | 2003-08-14 | — | — | WO | claimed |
| US-20020173510-A1 | Formulation for menopausal women | DRUGTECH CORPORATION | 2002-11-21 | — | — | US | claimed |
| US-6479545-B1 | Formulation for menopausal women | DRUGTECH CORPORATION | 2002-11-12 | — | — | US | claimed |
| US-20020137749-A1 | Formulation for menopausal women | DRUGTECH CORPORATION (US) | 2002-09-26 | — | — | US | claimed |
| EP-1216024-A1 | FORMULATION FOR MENOPAUSAL WOMEN | Drugtech Corporation (US) | 2002-06-26 | — | — | EP | claimed |
| WO-2001024772-A1 | FORMULATION FOR MENOPAUSAL WOMEN | DRUGTECH CORPORATION (US) | 2001-04-12 | — | — | WO | claimed |
| WO-2000077590-A1 | APPARATUS FOR CALCULATING TIME PERIODS AND FUTURE DATES | CRAIG H RANDALL (US) | 2000-12-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250268915-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SHBG, AR, CYP17A1 | ESR1 15/4885KDM4E 3258/4885KMT2A 4203/4885 |
| US-20250295670-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SHBG, AR, CYP17A1 | ESR1 15/4885KDM4E 3258/4885KMT2A 4203/4885 |
| US-12544387-B2 | Methods and compositions for testosterone production | SHBG, FSHR, GNRHR | ESR1 27/4885KDM4E 3190/4885KMT2A 3116/4885 |
| US-20250281505-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SHBG, AR, CYP19A1 | ESR1 11/4885KDM4E 2748/4885KMT2A 3988/4885 |
| US-20250288598-A1 | METHODS AND COMPOSITIONS FOR TESTOSTERONE PRODUCTION | SHBG, AR, CYP19A1 | ESR1 11/4885KDM4E 2748/4885KMT2A 3988/4885 |
| US-20250269005-A1 | METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENT | ZFX, ACE2, ZFR | ESR1 1685/4885KDM4E 303/4885KMT2A 641/4885 |
| US-20040029891-A1 | Use of PDE5 inhibitors in the treatment of polycystic ovary syndrome | PDE5A, PDE12, PDE2A | ESR1 3837/4885KDM4E 1325/4885KMT2A 2350/4885 |
| US-12533363-B2 | Methods and compositions for testosterone production | SHBG, FSHR, GNRHR | ESR1 27/4885KDM4E 2780/4885KMT2A 3523/4885 |
| US-12569624-B2 | Devices, methods and compositions for reproductive organs | PGF, GNRHR, PROX1 | ESR1 216/4885KDM4E 3274/4885KMT2A 4546/4885 |
| US-12533364-B2 | Methods and compositions for testosterone production | SHBG, FSHR, GNRHR | ESR1 27/4885KDM4E 2825/4885KMT2A 3389/4885 |
| US-20020137749-A1 | Formulation for menopausal women | SHBG, FABP6, BRCA1 | ESR1 17/4885KDM4E 3618/4885KMT2A 3096/4885 |
| US-20020173510-A1 | Formulation for menopausal women | SHBG, FABP6, BRCA1 | ESR1 17/4885KDM4E 3618/4885KMT2A 3096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.